European VitreoRetinal Society a certain philosophy

Levent Karabas, Hande Etus*, Bengu Yucel, Yusuf Çaglar (Kocaeli, Turkey) Advantages: To evaluate safety and efficacy of photodynamic therapy (PDT) with Verteporfin combined with intravitreal bevacizumab for choroidal neovascularization associated with angioid streaks. Methods: Six eyes of six patients treated with PDT with Verteporfin and 0, 05 mg/ml Bevacizumab injections were included. Standardized protocol, visual acuity (VA),...

Sin Woo Bae, Sung Jae Yang, Ju Byung Chae (Seoul, South Korea) Advantages: To compare metamorphopsia changes after two different central serous chorioretinopathy treatments with M-CHART (Inami Co., Tokyo, Japan). Methods: We compared 20 self-resolved eyes with oral medication and 10 eyes with low-fluence (LF) PDT. M-CHART, best corrected visual acuity (BCVA), and optical coherence tomography (OCT) were investigated. Effectiveness /...

Jung Yeul Kim (Daejeon, South Korea) Purpose: To evaluate the efficacy of intravitreal ranibizumab (Lucentis) with verteporfin photodynamic therapy (PDT) for patients with polypoidal choroidal vasculopathy (PCV). Patients and Methods: Seventeen eyes of 17 patients with symptomatic PCV who received three monthly intravitreal ranibizumab injections with PDT were retrospectively reviewed. The follow-up period lasted over 6 months after...

Michele Fortunato (Rome, Italy), Rossana Di Pietro (Pinerolo (TO) Italy) Advantages: Photodynamic therapy represents a safe and efficient procedure for the treatment of retinal angiomas in children, by the selective occlusion of vascular lesions, without damaging adjacent retinal structures. Methods: The authors describe their experience in the treatment of five cases of von Hippel Lindau disease; patients present the age between 5 and 9...

http://www.evrs.eu/medias/2010/congress/Central-Serous-Chorioretinopathy.flv Begoña Pina Marín, José Juan Escobar Barranco, Manel Fernández Bonet (Barcelona, Spain) Advantages: The physiopathology of central serous corioretinopathy (CSC) remains controversial. The traditional treatment includes laser photocoagulation or photodynamic therapy (PDT). Lately, ranibizumab, an anti-VEGF antibody, has shown anti-permeable properties that...

Isaac Alarcon, Daniel Vilaplana, Vladimir Poposki, M. Castilla, Xavier Acebes (Barcelona, Spain) Advantages: Photodynamic therapy (PDT) can be a useful and powerful tool to treat the different clinical forms of Central Serous Chorioretinopathy (CSC) and its possible complications. Methods: Classic CSC: PDT can be useful to treat CSC specially when the patient suffers more than one episode from the same focal leak in the fundus. We show...

http://www.evrs.eu/medias/2010/congress/Age-Related-Macular-Degeneration-2.flv Guy L’Helgoual’ch (Brest, France) Advantages: Early evaluation with spectral domain OCT of the anatomical modifications of the various retinal layers after PDT, illustrates the need for adjuvant therapy. Methods: Standard parameters were used with respect to Visudyne dose, perfusion, wash out duration, and diode laser power setting. Low fluence was...

http://www.evrs.eu/medias/2010/videos/SooGeunJoe_VP6_768K.flv Soo Geun Joe, Jong Uk Hwang, Joo Yong Lee, June-Gone Kim (Seoul, South Korea) Advantages: The authors will discuss their successful management of massive suprachoroidal hemorrhage with secondary angle closure glaucoma, which developed after photodynamic therapy (PDT) combined with intravitreal bevacizumab injection (IVB) for age-related macular degeneration (ARMD). In this...

http://www.evrs.eu/medias/2009/congress/Combined-Treatments.flv Author: Taehyuk Koh, South Korea Advantages: To evaluate the one year outcome for monotherapy of avastin and combined therapy of avastin plus photodynamic therapy (PDT). Methods: Monotherapy group was received avastin 3 times every 6 weeks. In combination group, we started intravitreal avastin one week before and after PDT in the same way. In 49 eyes, we evaluated vision,...

http://www.evrs.eu/medias/2009/congress/Combined-Treatments.flv Authors: Raimondo Forte, Naples, Italy; Michael J. Potter, Cheryl Claudio, Shelagh M. Szabo, Vancouver, Canada Advantages: To obtain a greater improvement after treatment of choroidal neovascularization (CNV) due to age-related macular degeneration (AMD). Methods: Prospective, randomized, double masked, controlled, interventional study. Thirty five eyes (35 patients) presenting...

http://www.evrs.eu/medias/2009/congress/Combined-Treatments.flv Authors: Raimondo Forte, Paola Bonavolontà, Naples, Italy; Jean Paul Adenis, Pierre-Yves Robert, Limoges, France Advantages: To reduce the number of retreatments with intravitreal anti- VEGF in exudative age related macular degeneration (AMD). Methods: We evaluated all eyes with exudative AMD treated with bevacizumab or ranibizumab in monotherapy and in association with...

http://www.evrs.eu/medias/2009/congress/Combined-Treatments.flv Authors: Rosa Maria Romero-Castro, Alfredo Morales, H. Quiroz-Mercado, Mexico Advantages: New modality treatmens are needed to increase effectiveness and reduce number of retreatmens in AMD patients. Triple therapy with PDT, intravitreal triamcinolone and intravitreal ranibizumab can be with less number of treatments and they’re for less cost a safe treatment option for...

http://www.evrs.eu/medias/2008/congress/Combined-Photodynamic-Therapy-with-Intravitreal-Bevacizumab-for-Neovascular-ARMD.flv Young Ju Lew, Moon Jung Choi, Tae Gon Lee, Sung Won Cho, (Kim,’s Eye Hospital, Konyang Universtiy, Seoul, Korea ), Eun Jee Chung (NHIC, Ilsan Hospital, Gyunggido, Korea), Sung Woo Ha (Bungdang CHA General Hospital, Pochun CHA University, Guyunggido, Korea) Advantages: To investigate the efficacy of combined...

http://www.evrs.eu/medias/2008/congress/Combined-Bevacizumab-and-Photodynamic-Theraphy-in-ARMD.flv V. Levent Karabaþ, Berna Özkan, Özgül Altýntaþ, Nurþen Yüksel, Yusuf Çaðlar Advantages: Combination of bevacizumab with PDT led to decreased need for recurrent injections of bevacizumab. Methods: The records of 62 patients who had combined bevacizumab injection and PDT for Age Related Macular Degeneration between March 2006 and...

Osman Cekic, Mehmet Cakir, Omer F. Yilmaz Advantages: To report the result of photodynamic therapy (PDT) for an iatrogenic choroidal neovascularization (CNV) complicating focal argon laser coagulation in a case with central serous chorioretinopathy. Methods: A 45-year-old woman that developed CNV upon focal argon laser photocoagulation for chronic central serous chorioretinopathy was treated with ocular PDT with verteporfin. Effectiveness...

Osman Cekic, Mehmet Cakir, Cengiz Alagoz, Nese Alagoz, Omer F. Yilmaz Advantages: To demonstrate the effectiveness of triple therapy in patients with subfoveal choroidal neovascular membrane (SCNM) related to age-related macular degeneration (AMD). Methods: Twenty-nine eyes of 26 patients (10 male, 16 female, mean age: 71.2 years) with SCNM that underwent triple therapy were evaluated retrospectively. Intravitreal injection of 2 mg...

Alay S. Banker, Ajay Dudani, Ashish Vaidya, Rohan Chauhan, Urvashi Goja Advantages: Combination therapies (half-fluence photodynamic therapy and intravitreal Anti-VEGF) lead to better chances of improved vision and fewer repeat treatments in cases of choroidal neovascularization. Methods: Prospective study of 36 eyes treated with single half-fluence Photodynamic therapy (PDT) + 3 monthly intravitreal ranibizumab (IL). ETDRS visual acuity...

http://www.evrs.eu/medias/2008/congress/Photodynamic-Therapy:-Focal-Treatment-for-Idiopathic-Polypoidal-Choroidal-Vasculopathy.flv Daniel Vilaplana, Vladimir Poposki, Daniel Martin, Isaac Alarcon, Miguel Castilla Advantages: The focal (selective) treatment with photodynamic therapy (PDT) to treat idiopathic polypoidal choroidal vasculopathy (IPCV) has the advantage of producing minimum changes in the choroid and pigment epithelium. Methods:...

http://www.evrs.eu/medias/2008/congress/3D-OCT-Guided-Photodynamic-Therapy-in-Cases-of-Retinochoroidal-Anastomoses.flv Ioannis P. Theocharis Advantages: To avoid interventional diagnostic tests such as FA and ICG, using the point to point registration software of Topcons 3D OCT in cases where PDT is indicated, with ensuing benefit in terms of cost of treatment and avoidance of the risks of FA and ICG. Methods: Measurement of the treatment...

http://www.evrs.eu/medias/2007/videos/newvessels.flv

Guy l’Helgoualch, MD (Brest, France) PURPOSE: To check using Avastin in intravitreous injection reduces the surface and the thickness of the neovascular membrane. To check improving the effect of PDT and reducing the side effects increases the final visual acuity. To verify this protocol of tritherapy reduces the number of treatment during the period of follow-up. METHODS: The population of patients includes the same proportion of...

Albert J. Augustin, MD (Sulzfeld, Germany), Indre Offermann, MD (Karlsruhe, Germany), Stephan Puls, MD (Karlsruhe, Germany), Frank H.J. Koch, MD (Frankfurt am Main, Germany), Ursula Schmidt-Erfurth, MD (Vienna, Austria)* PURPOSE: To assess the treatment and outcome of patients with CNV treated with PDT combined with intravitreal triamcinolone (TA). METHODS: Patients (n? 307) suffering from CNV (76.2% subfoveal, 12.1% juxtafoveal, 11.7%...

Asheesh Tewari, MD (St. Louis, MO), Rajendra S. Apte, MD, PhD (St. Louis, MO)* PURPOSE: To examine outcomes of a group of previously treatment naïve patients treated with combined photodynamic therapy with verteporfin and intravitreal pegaptanib for choroidal neovascularization secondary to ARMD. METHODS: Retrospective review of ten eyes of ten consecutive patients with CNV secondary to ARMD. These patients had  not received  any prior...

http://www.evrs.eu/medias/2006/congress/Six-month-Results-of-a-Randomized,-Double-masked,-Controlled-Trial-of-Intravitreal-Triamcinolone-as-an-Adjunct-to-Photodynamic-Therapy-in-Predominantly-Classic-Neovascular-Age-related-Macular-Degeneration:-The-Canadian-RETINA-Study.swf David Maberley, MD, FRCSC, MSc (Vancouver, Canada),* PURPOSE: To compare safety data and ETDRS visual acuity outcomes data for one-hundred subjects with predominantly...

Olcay Tatar, (Tuebingen, Germany), Annemarie Adam, (Tuebingen, Germany), Kei Shinoda, MD, PhD (Tokyo, Japan), Peter Stalmans, MD, PhD (Leuven, Belgium), Claus Eckardt, MD (Frankfurt, Germany), Matthias Lüke, MD (Tuebingen, Germany), Karl Ulrich Bartz-Schmidt (Tuebingen, Germany), Salvatore Grisanti, MD (Tuebingen, Germany) PURPOSE: To examine the impact of photodynamic therapy (PDT) on pigment epithelium derived factor (PEDF) expression...

Ivan J. Suner, MD (Durham, NC)* PURPOSE: Currently employed treatment strategies for AMD include photodynamic therapy (PDT) that is essentially photo-ablative and vaso-occlusive, pharmacologic blockade of VEGF that can be both selective and non-selective, and pharmacotherpy primarily directed at modulating the immune response. This study assesses the relative systemic safety of these several approaches. METHODS: Safety profiles of PDT were...

http://www.evrs.eu/medias/2006/congress/The-Effect-of-Kenalog-as-Adjunctive-Treatment-to-Visudyne-in-Minimally-Classic-and-Occult-Neovascular-AMD:-A-Prospective,-Randomized-Clinical-Trial.swf Tom Sheidow, MD, FRCS(C) (London, Canada), Varun Chaudhary, MD (London, Canada), Phil Hooper, MD, FRCSC (London, Canada), Alex Mao, MD (London, Canada) PURPOSE: To evaluate the mean change is ETDRS visual acuity score from baseline and the number of...

http://www.evrs.eu/medias/2006/congress/Combined-Intravitreal-Triamcinolone-with-Photodynamic-Therapy-for-the-Treatment-of-Choroidal-Neovascularization-in-Age-Related-Macular-Degeneration.swf Catherine Favard, MD (Paris, France), Valerie Krivosic, MD (Paris, France), Lucie Machado, DO (Paris, France), Michael Assouline, MD, PhD (Paris, France), Catherine Francais, MD (Paris, France) PURPOSE: To determine whether photodynamic therapy (PDT)...

Gÿng.sr Sobaci, MD (Ankara, Turkey), Melih Osman Çeylan, MD (Ankara, Turkey), Sayih Altun, MD (Ankara, Turkey), Seçkin Aykas, MD (Anakar, Turkey), Mehmmet Zeki Bayraktar, MD (Ankara, Turkey) PURPOSE: We previously showed that hypericin, the most powerful natural photoactive pigment can induce development of photothrombosis in the choriocapillaries when activated with argongreen laser at light fluences causing subthreshold burn Efficacy...

Stephen H. Sinclair, MD (Media, PA),* Weiye Li, MD (Media, PA), Peter Presti, (Media, PA)* PURPOSE: Vision outcomes for treatment of AMD CNVM have been previously evaluated using visual acuity with severe limitations. Central visual field testing with discriminated targets appears to offer significant advantages. METHODS: In this cohort, 31 eyes of 29 patients undergoing PDT with intravitreal triamcinolone for AMD CNVM underwent IVFA, BCVA...

Arturo Santos, MD, PhD (Guadalajara, Mexico), Enrique A. Roig-Melo, MD PhD (Guadalajara, Mexico), Ramon Flores-Fuentes, MD (Guadalajara, Mexico), Juan C. Altamirano, MD (Guadalajara, Mexico) PURPOSE: To evaluate the feasibility and safety of the combination of photodynamic therapy with verteporfin (PDT), intravitreal Bevacizumab and preservative free Triamcinolone acetonide (PFTA) for the treatment of exudative AMD. METHODS: This is a...

Frank H.J. Koch, MD (Frankfurt am Main, Germany),* Albert J. Augustin, MD (Karlsruhe, Germany), Robert G. Josephberg, MD (Yonkers, NY),* K. Peter Luloh, (Sanford, FL),* Indre Offermann, MD (Karlsruhe, Germany), Shahrzad Ghozisad, MD (Frankfurt am Main, Germany), Joachim Puchta, MD (Frankfurt am Main,Germany), Pankaj Singh, MD (Frankfurt Am Main, Germany) PURPOSE: A treatment regimen that combines photodynamic therapy (PDT) with a core pars...

Michael J. Potter, MD (Vancouver, Canada),* Shelagh M. Szabo, BSc (Vancouver, Canada) PURPOSE: To compare the incidence of recurrence of CNV at 18 months after treatment with photodynamic therapy (PDT) with verteporfin, and PDT plus intravitreal Kenalog (IVT), in patients with age-related macular degeneration. METHODS: This is a prospective study of consecutive patients treated with PDT alone, or PDT plus IVT at baseline. Final treatment...

http://www.evrs.eu/medias/2006/congress/Combination-Avastin-and-Reduced-Fluence-Photodynamic-Therapy-for-Choroidal-Neovascularization.swf David Callanan, MD (Arlington, TX),* Wayne Solley, MD (Arlington, TX) PURPOSE: The purpose of the study is to determine whether the combination of intravitreal Avastin and reduced fluence PDT is as effective as either treatment alone; and whether the combination therapy may reduce the number of treatments...

Ayala Pollack, MD (Rehovot, Israel), Amir Bukelman, MD (Rehovot, Israel), Gennady Landa, MD (Ashkelon, Israel), Yoel Greenwald, MD (Jerusalem, Israel), Haya Katz, MD (Rishon Lezion, Israel), Hana Leiba, MD (Yavneh, Israel) PURPOSE: To evaluate the relationship between cataract surgery, AMD, and PDT outcome. METHODS: All patients underwent both PDT for wet AMD, and cataract surgery by phacoemulsification. They were divided into three...

Gaurav K. Shah, MD (St. Louis, MO), Mandeep S. Dhalla, MD (St. Louis, MO), Kevin J. Blinder, MD (St. Louis, MO), Edwin H. Ryan, MD (Minneapolis, MN), Robert A. Mittra, MD (Minneapolis, MN), Asheesh Tewari, MD (St. Louis, MO) PURPOSE: To examine the 6-month results of a group of patients treated with combined photodynamic therapy (PDT) with verteporfin with intravitreal bevacizumab for choroidal neovascularization (CNV) secondary to...

Rajeev Hemant Muni, MD (Toronto, Canada), Mike Altaweel, MD (Madison, WI), Matt T. Tennant, MD (Edmonton, Canada), Bruce Weaver, BSc, MSc (Thunder Bay, Canada), Peter J. Kertes, MD, FRCS(C) (Toronto, Canada) PURPOSE: To determine the inter- and intra-observer agreement among Canadian retina specialists in the determination of treatment eligibility for photodynamic therapy and the angiographic classification of CNV. Agreement was also...

http://www.evrs.eu/medias/2006/congress/Combination-Therapy-for-Wet-Age-related-Macular-Degeneration-Using-Verteporfin-Photodynamic-Therapy-and-Intravitreal-Bevacizumab.swf Jose Dalma-Weiszhausz, MD (Mexico City, Mexico), Maura Lucy Abraham Marin, MD (Mexico City, Mexico), Carlos Fernando Cortes Luna, MD (Bogota, Colombia), Ana Suarez- Lincona, MD (Mexico City, Mexico), Griselda Alvarez-Rivera, MD (Mexico City, Mexico), Orlando Ustariz...

Derek L. Barker, MD (Tallahassee, FL), H. Logan Brooks, MD (Tallahassee, FL), Robert L. Steinmetz, MD (Tallahassee, FL), Charles K. Newell, MD (Tallahassee, FL), Carmen A. Puliafito, MD (Miami, FL), Philip J. Rosenfeld, MD, PhD (Miami, FL) PURPOSE: Is bevacizumab more effective at preventing vision loss from juxtafoveal macular degeneration than photodynamic therapy? METHODS: A six month retrospective analysis of patients with juxtafoveal...

Mun-Wai Lee, MD (Singapore, Singapore), Doric Wong, FRCS(Ed) (Singapore, Singapore) PURPOSE: To describe the efficacy of photodynamic therapy (PDT) in the treatment of idiopathic polypoidal choroidal vasculopathy (IPCV). METHODS: Retrospective analysis of a consecutive series of patients who presented with symptomatic serosanguineous maculopathy secondary to IPCV. All patients had indocyanine green defined lesions and underwent PDT with...

Jaco Lavinsky, MD (Porto Alegre, Brazil), Daniel Lavinsky, MD (Sao Paulo, Brazil), Fabio Lavinsky, MD (Ramat Gan, Israel) PURPOSE: Currently, there are several new therapeutic strategies for exudative AMD being studied, and the main target has been to occlude neovascularization and to obtain an antiangiogenic and antipermeability effect. Our purpose was to study the influence of vascular leakage on the angiographic outcome of Photodynamic...

Noha Khater, (Cairo, Egypt), Hoda, MH Mostafa, MD (Cairo, Egypt), Mahmoud Soliman (Cairo, Egypt), Tamer Macky, MD (Cairo, Egypt) PURPOSE: To evaluate the outcomes of combined intravitreal triamcinolone (IVTA) and photodynamic therapy (PDT) in the treatment of subfoveal choroidal neovascularization (CNV) caused by age related macular degeneration (AMD) and myopia. METHODS: Fifteen eyes from 15 patients with subfoveal CNV caused by AMD (n=10)...

Peter K. Kaiser, MD (Cleveland, OH)* PURPOSE: The VeriTAS study is designed to evaluate the efficacy and safety of verteporfin PDT combined with either intravitreal triamcinolone acetonide or pegaptanib sodium to treat subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD). The 24-month randomized, double-masked VeriTAS study enrolled patients at 50 centers in the U.S. METHODS: Inclusion criteria:...

ThucAnh Thi Ho, MD (Chicago, IL), Pauline Townsend Merrill, MD (Chicago, IL) PURPOSE: To evaluate the role of combined intravitreal pegaptanib and photodynamic therapy with verteporfin (PDT) in the management of subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD). METHODS: We performed a retrospective review on 11 eyes of 11 patients treated with combined pegaptanib and PDT. Pre-treatment and...

http://www.evrs.eu/medias/2006/congress/Prolonged-Choroidal-Hypofluorescence-Following-Verteporfin-PDT-Combined-with-Intravitreal-Triamcinolone-Acetate-Injection-for-Agerelated-CNVM.swf Jeffrey K. Luttrull, MD (Ventura, CA), Charles A Spink, CRA (Ventura, CA) PURPOSE: To determine the incidence and effect of prolonged choroidal hypofluorescence (PCH) following combined verteporfin photodynamic therapy and intravitreal triamcinolone acetate...

Salvatore Grisanti, MD (Tuebingen, Germany), Olcay Tatar, MD (Tuebingen, Germany), Kei Shinoda, MD, PhD (Tokyo, Japan), Annemarie Adam, (Tuebingen, Germany), Klaus Lucke, MB ChB (Bremen, Germany), Claus Eckardt, MD (Frankfurt, Germany), Peter Stalmans, MD, PhD (Leuven, Belgium), Tillmann Eckert, MD (Frankfurt, Germany), Silvia Bopp, MD (Bremen, Germany), Karl Ulrich Bartz-Schmidt (Tuebingen, Germany) PURPOSE: To evaluate the impact of...

Paul B. Griggs, MD (Seattle, WA), Richard C. Lee, BS (Seattle, WA) PURPOSE: To review the clinical results of sequential pegaptanib monotherapy following verteporfin photodynamic therapy for choroidal neovascularization. METHODS: Patients were identified in which pegaptanib therapy was initiated following initial treatment of choroidal neovascularization with verteporfin photodynamic therapy with or without adjuvant intravitreal...

Leila El Matri, MD (Tunis, Tunisia), Fatma Mghaieth, MD (Tunis, Tunisia), Rym Bouraoui, MD (Tunis, Tunisia), Rim Limaiem, MD (Tunis, Tunisia), Sihem Meddeb, MD (Tunis, Tunisia) PURPOSE: To evaluate results and prognosis of photodynamic therapy in choroidal neovascularisation secondary to pathologic myopia and to identify potential relation between the visual outcome and the age at presentation. METHODS: Retospective study from February...

Ajay Dudani, MD (Mumbai, India), Alay S Banker, MD (Ahmedabad, Gujarat, India), J. Fernando Arevalo, MD, FACS (Caracas, Venezuela) PURPOSE: To examine the 12-month results of a group of patients treated with combined photodynamic therapy (PDT) with verteporfin and intravitreal triamcinolone acetonide for choroidal neovascularization (CNV). METHODS: Retrospective analysis of noncomparative case series of 54 eyes with CNV which were treated...

Lucian V. Del Priore, MD, PhD (New York, NY), Ankoor R. Shah, BS (New York, NY) PURPOSE: Multiple pharmacological treatments (photodynamic therapy [PDT], Macugen, Lucentis, and Anecortave Acetate [AA]) exist for exudative AMD; typically these treatments are compared to controls in clinical trials but not to one another. We have shown the rate of visual loss in untreated eyes is linear on a double reciprocal Lineweaver-Burke (LB) plot with...

http://www.evrs.eu/medias/2006/congress/The-Value-and-Cost-effectiveness-of-Interventions-for-Subfoveal,-Neovascular,-Age-related-Macular-Degeneration-(ARMD).swf Melissa M. Brown, MD, MN, MBA (Flourtown, PA),* Gary C. Brown, MD, MBA (Wyndmoor, PA)* PURPOSE: To assess the value of interventions utilized for the treatment of subfoveal, neovascular, agerelated macular degeneration (ARMD) employing evidencebased data from clinical trials...

Edwin H. Ryan, MD (Minneapolis, MN)* PURPOSE: A masking device or method to create custom PDT laser exposure patterns would be desirable in multiple settings. This study tests the feasibility of a prototype of such a masking device and method. Such a method would optimally be reproducible, accuratelypatterned, and simple to use. It should also have a distinct margin, visible to the treating physician. METHODS: A site was identified in the...

Francesco Boscia, MD (Bari, Italy), Ugo Introini, MD (Milano, Italy), Alfredo Pece, MD (Melegnano (mi), Italy), Francesco Prascina,  MD (Foggia, Italy), Michele Reibaldi, MD (Catania, Italy), Claudio Furino, (Bari, Italy), Caterina Papadopolou, MD (Bari, Italy), Giancarlo Sborgia, MD (Bari, Italy) PURPOSE: Large randomized clinical trials of laser photocoagulation, photodynamic therapy (PDT) with verteporfin and antiangiogenic drugs have...

Gregory R. Blaha, MD, PhD (Peabody, MA), Jeffrey L. Marx, MD (Peabody, MA)* PURPOSE: To report our experience with combination low-fluence PDT. METHODS: An IRB-approved, retrospective chart review of all patients receiving low-fluence (50% standard) PDT (LFPDT) at our institution was performed. RESULTS: Twenty five eyes of 24 patients received LFPDT. Two eyes did not receive combination therapy, two received Macugen (Pegaptanib,...

Alay S. Banker, MD (Ahmedabad, India), J. Fernando Arevalo, MD, FACS (Caracas, Venezuela), Ajay Dudani, MD (Mumbai, India) PURPOSE: To determine the results of combination triple therapy for choroidal neovascularization (CNV). METHODS: Prospective pilot study of 11 consecutive eyes with new (previously untreated) CNV which were treated with photodynamic therapy (PDT) with visudyne along with intravitreal bevacizumab (1.25mg) and subtenon...

Sebastian Wolf, MD (Bern, Switzerland),* Thomas C. Hohman, PhD (East Hanover, NJ),* PROTECT Study Group PURPOSE: To evaluate the safety and explore the efficacy of same-day administration of verteporfin and intravitreal injection of liquid ranibizumab 0.5mg. METHODS: PROTECT is an open label, multicenter, Phase II, 9 month study, in patients with predominantly classic (n=13) or occult (n=19), subfoveal CNV secondary to AMD. Verteporfin was...

http://www.evrs.eu/medias/2006/congress/Intravitreal-Ranibizumab-(LucentisTM)-Plus-Verteporfin- Photodynamic-Therapy-for-Neovascular-Age-related-Macular- Degeneration:-FOCUS-2-year-Results.swf Andrew N. Antoszyk, MD (Charlotte, NC),* Debbi Kotlovker, (San Francisco, CA),* Sharon O’Byrne, (San Francisco, CA)* PURPOSE: The 2-year FOCUS study compared the safety and efficacy of monthly intravitreal injections of ranibizumab (Lucentis) in...

Enrico Bertelli, (Bolzano, Italy) PURPOSE: To assess the efficacy of ICG mediated phototrombosis in the treatment of large vascular lesions, and in particular of a 6 mm large, actively exudating retinal hemangioblastoma in a case of von Hippel- Lindau disease. METHODS: A 31 year old female patient presented with history of decreased vision in her right eye dating back several months. Visual acuity had decreased to 20/200. Fundus examination...

http://www.evrs.eu/medias/2006/congress/Combined-Photodynamic-Therapy-with-Verteporfin-and-Intravitreal-Bevacizumab-for-Subfoveal-Choroidal-Neovascularization-in-AMD.swf David M. Misch, MD (Winter Haven, FL), Michael J. Tolentino, MD (Winter Haven, FL),* Adam S. Berger, MD (Winter Haven, FL), Suk Jin Moon, MD (Winter Haven, FL) PURPOSE: To determine the safety and efficacy of combined intravitreal Bevacizumab (Avastin) with photodynamic...

http://www.evrs.eu/medias/2005/congress/Anecortave-Acetate-depot-suspension-for-treatment-of-exudative-age-related-macular-degeneration (AMD).swf Marc De Smet, MD, PhD – Department of Ophthalmology, University of Amsterdam and the Anecortave Acetate Clinical Study Purpose: To report data from Phase II/III studies evaluating Anecortave Acetate for depot suspension for treatment of exudative AMD. Studies include 1) 24 month study of...

http://www.evrs.eu/medias/2005/congress/Combined-treatment:-Photodynamic-therapy-with-visudyne-and-intravitreous-injection-of-triamcinolone-(IVT).swf Guy L’Helgoual’ch Purpose: To estimate the interest of intravitreous injection of Triaminolone 24 hours after Photodynamic Therapy with Visudyne used as treatment of néovascular complications of age related macular degeneration. Methods: During a period longer than 2 years, each patient...

http://www.evrs.eu/medias/2005/congress/Histological-charateristics-of-neovascular-membranes-in-AMD-after-PDT:-Comparison-with-spontaneous-evolution,-laser-photocoagulation-and-radiotherapy.swf Didier Ducournau, Nantes, France, Yvette Ducournau – Nantes, France Purpose: To describe and emphasize specific histological changes observed on removed neovascular membranes after PDT in order to understand the post treatment complication and the...

Guy L’Helgoual’ch Purpose: To analyse the photodynamic therapy’s complications and try to understand parts of the mecanisms. Methods: Fluorescein and ICG angiograph are done using a Topcon Imagenet system Adobe Photoshop software to analyse the pictures and create traces from the lesion and laser’s spot area Morphing software to compare the angiographs. Results: Using Adobe photoshop software, it is possible to show the...

http://www.evrs.eu/medias/2005/congress/Photodynamic-Therapy-for-Choroidal-Neovascularization-in-Juvenile-Disciform-Macular-Degeneration.-Case-Report-of-Four-Icelandic-Cases.swf Ingimundur Gislason, MD, Fridbert Jonasson, MD, Thordur Sverrisson, MD – Department of Ophthalmology, Landspitali University Hospital, Reykjavik, Iceland Purpose: To evaluate the result of PDT treatment for choroidal neovascularization in juvenile disciform...

http://www.evrs.eu/medias/2005/congress/Photodynamic-therapy-in-the-treatment-of-retinal-angiomatous- proliferation-(RAP).swf Márcio Nehemy, MD, PhD, Erika Magalhães, MD, PhD, Patrícia Nehemy, MD Purpose: To evaluate photodynamic therapy (PDT) for retinal angiomatous proliferation (RAP). Methods: Thirty eight eyes of thrity one consecutive patients with RAP were treated with PDT. Fifteen of these eyes received also an intravitreous...

http://www.evrs.eu/medias/2005/congress/Encouraging-results-of-photodynamic-therapy-with-verteporfin-in-a-clinical-patient-material-of-age-related-macular-degeneration-and-choroidal-neovascularization.swf Christina Frennesson, MD, PhD, Sven Erik Nilsson, MD, PhD Purpose: To investigate the effects of photodynamic therapy (PDT) on sub- and juxtafoveal choroidal neovascularization (CNV) in age-related macular degeneration (AMD) in a clinical...

http://www.evrs.eu/medias/2005/congress/One-year-results-of-photodynamic-therapy-in-eyes-with-choroidal-neovascular-membranes-due-to-age-related-macular-degeneration.swf Tugrul Altan, Ziya Kapran, Mehmet Cakir, Nur Acar, Yaprak B. Unver, Zerrin Bayraktar Purpose: To evaluate the effectiveness of photodynamic therapy with verteporfin in preserving vision at 1 year in eyes with CNVM due to ARMD. Methods: 44 eyes of 43 patients who had...

Malbrel Christian Purpose: Control innocuity of different therapies used in ARMD on color vision and central sensitivity. Methods: PDT-TTT-intravitreous triamcinolone-exerese surgery-radiotherapy were used on several patients with long survey time. Color vision and macular sensitivity data were collected. Results: About 1000 data on several years showing evolution of illness and influence of therapy. Conclusion: PDT is a safeguard for...

http://www.evrs.eu/medias/2005/congress/Hypothesis:-Is-vitreous-adhesion-a-risk-factor-for-CNV-in-AMD.swf Martine Mauget-Faÿsse, Maddalena Quaranta El Maftouhi, Margara Zanotele, François Devin Purpose: The relationships between posterior vitreous and retina have been poorly described in vivo in exudative AMD. In a previous study (ARVO 2003), high prevalence of abnormalities of the vitreo-retinal interface have been found in exudative AMD...

F. Gelisken, K. U. Bartz-Schmidt for the Tuebingen Study Group Purpose: To report the change of the mean visual acuity of the patients enrolled in the Full Macular Translocation (FMT) vs. Verteporfin Photodynamic Therapy (PDT) study for subfoveal, predominantly classic choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD). Design Monocenter, prospective, controlled, randomized, clinical, pilot study....